Open research questions in Sirtuins and Resveratrol in Medicine
411 gap statements mined from Sirtuins and Resveratrol in Medicine papers in our 7.9M-paper local library, which holds 1,268 papers on the topic — drawn mostly from each paper's own stated research gap, future-work, challenge and limitation notes, and its abstract. The ones listed below are a selection still marked open; each names the study that raised it, with a DOI link where the paper has one.
Choosing where to publish on Sirtuins and Resveratrol in Medicine? See the ranked Medicine journals.
What the literature leaves open
Further studies are needed to fully elucidate the mechanisms by which the C/EBPβ/AEP pathway contributes to vascular deterioration and systemic aging. Investigations into the therapeutic potential of targeting the C/EBPβ/AEP pathway in humans are warranted. Research into the role of other pathways and factors in mediating aging-related pathologies is necessary.
The underlying molecular mechanisms driving vascular deterioration remain poorly understood. The role of the C/EBPβ/AEP pathway in vascular aging and systemic frailty is not well understood. There is a need for therapeutic strategies to preserve vascular integrity and mitigate systemic frailty in aging populations.
One of the challenges is the limited therapeutic index of phenytoin, making it easy to reach toxic levels. Another challenge is the need to evaluate cerebellar functions and morphology in rats treated with phenytoin and dapagliflozin. The study also faces the challenge of investigating the role of the SIRT1/Nrf2/HO-1 pathway in the protective effect of dapagliflozin.
Protective effect of dapagliflozin against phenytoin-induced cerebellar dysfunction and histological alterations in rats: the role of SIRT1/Nrf2/HO-1 pathway · 2026 · DOIThere is a need to investigate the protective role of dapagliflozin against phenytoin-induced cerebellar dysfunction in rats. The current study aims to fill this gap by evaluating cerebellar functions and morphology in rats treated with phenytoin and dapagliflozin.
Protective effect of dapagliflozin against phenytoin-induced cerebellar dysfunction and histological alterations in rats: the role of SIRT1/Nrf2/HO-1 pathway · 2026 · DOIThe complexity of prostate cancer progression and the need for a better understanding of the underlying mechanisms. The challenge of developing effective therapeutic strategies for metastatic prostate cancer.
The study did not investigate the in vivo efficacy of the ASDs. The study used a limited number of polymers (PVP K30 and VA64) and did not explore other potential polymers. The study did not evaluate the long-term stability of the ASDs.
Enhanced Antioxidant and Neuroprotective Properties of Pterostilbene (Resveratrol Derivative) in Amorphous Solid Dispersions · 2024 · DOIIt highlights the need for further research on the effects of resveratrol on age-related infertility, polycystic ovary syndrome, and endometriosis.
Nanoformulations may improve exposure, but depression specific clinical validation is lacking.
Resveratrol in depression: mechanistic networks, preclinical evidence and translational perspectives · 2026 · DOISex influences early-life immunity and infection outcomes, yet how metabolic mechanisms regulate these effects remain unclear.
SIRT7 is linked to cancer, yet its function in gastric cancer (GC) remains unclear.
SIRT7 Mediated‐PTEN Desuccinylation Drives Gastric Tumorigenesis by Activating PI3K/AKT Pathway · 2026 · DOIDespite the understanding of these outcomes, it remains unclear how glucocorticoid excess affects the metabolically critical nicotinamide adenine dinucleotide (NAD+) and related metabolites and transcripts, including redox cofactors, intermediates and biosynthetic enzymes.
There is limited information, however, about the biosynthetic pathways that replenish intracellular NAD+, which is continuously turned over in undifferentiated mouse embryonic stem cells.
Nicotinamide salvage is required for proliferation and sustaining self-renewal in undifferentiated embryonic stem cells · 2025 · DOIKnee osteoarthritis (OA) and frailty share pathophysiological processes and are leading causes of disability in the geriatric population; however, effective interventions remain elusive.
Resveratrol treatment increases sirtuin 1 levels and alleviates frailty phenotype in knee osteoarthritis patients: a randomised placebo-controlled clinical trial · 2025 · DOIMyocyte enhancer factor 2A (MEF2A), a transcription factor implicated in coronary artery disease, remains unexplored in vascular redox regulation.
Myocyte enhancer factor 2A orchestrates vascular redox homeostasis via direct transcriptional activation of SIRT1 · 2025 · DOIIn HCC samples, NAD-dependent deacetylase sirtuin 2 (SIRT2) levels are increased and associated with a significantly worse prognosis, but the role of SIRT2 in hepatocarcinogenesis remains controversial.
Suppression of Hepatocellular Carcinoma by Deletion of SIRT2 in Hepatocytes via Elevated C/EBPβ/GADD45γ · 2025 · DOIWhether Nicotinamide adenine dinucleotide supplementation may be beneficial for delirium has not been explored yet.
Acute Nicotinamide Adenine Dinucleotide Supplementation via Nicotinamide Mononucleotide Does Not Rescue Functional Impairment in a Lipopolysaccharide-induced Delirium Mouse Model · 2025 · DOIThe relationship between SIC and protein acetylation, particularly the balance between acetylation and deacetylation in cardiomyocyte subcellular structures, as well as how nuclear–mitochondrial coordination maintains standard antioxidant stress capacity, remains unclear.
SIRT3-FOXO3a Isoforms Forge Nuclear–Mitochondrial Links to Combat Sepsis-Induced Cardiomyopathy Oxidative Stress in Mice · 2025 · DOIThe largest gap is long-term safety, as NAD biology intersects with DNA repair, immune surveillance, inflammation, and cellular proliferation. There is no evidence that NAD boosters cause cancer, but it is equally improper to assume long-term safety without outcomes-based trials.
NAD⁺ Injections and NAD Boosters: Evidence Gaps, Safety Concerns, and Public Health Implications · 2026 · DOIThe need for a safer alternative to mitigate MP-induced hepatotoxicity. The lack of understanding of the potential health concerns of MP exposure.
Mitigating methylparaben hepatotoxicity: Resveratrol’s role in oxidative stress, inflammation, and apoptotic modulation · 2026 · DOIFurther research employing oral administration at clinically relevant doses, alongside pharmacokinetic evaluations and larger sample sizes, is essential to confirm these findings and advance the clinical translation of RES.
Mitigating methylparaben hepatotoxicity: Resveratrol’s role in oxidative stress, inflammation, and apoptotic modulation · 2026 · DOIWhile promising results have been observed in animal studies and some human trials, the overall evidence is mixed.
Effects of resveratrol supplementation on inflammatory markers, fatigue scale, fasting blood sugar and lipid profile in relapsing-remitting multiple sclerosis patients: a double-blind, randomized placebo-controlled trial · 2024 · DOIThis paper is a narrative synthesis and does not constitute a systematic review or meta-analysis. The clinical evidence base is evolving, and future long-duration trials may change benefit–risk assessments. Specific regulatory details vary by jurisdiction; this analysis emphasises internationally relevant public health principles and widely cited regulatory evidence.
NAD⁺ Injections and NAD Boosters: Evidence Gaps, Safety Concerns, and Public Health Implications · 2026 · DOIDirected research into better treatment options with resveratrol, - Investigation of the therapeutic potential of halogenated RSV derivatives, - Exploration of the use of nanoparticles to enhance the bioavailability…
Enhancing the Bioavailability of Resveratrol: Combine It, Derivatize It, or Encapsulate It? · 2024 · DOIInvestigation of the in vivo efficacy of the ASDs. Exploration of other potential polymers for ASD preparation. Evaluation of the long-term stability of the ASDs. Investigation of the potential applications of ASDs in various diseases.
Enhanced Antioxidant and Neuroprotective Properties of Pterostilbene (Resveratrol Derivative) in Amorphous Solid Dispersions · 2024 · DOIDeveloping NAPRT inhibitors to be utilized together with NAMPT inhibitors against PH-activated tumors, - Investigating the potential of NMNAT inhibition in cancer therapy, - Exploring alternative NAD + -producing routes that could be relevant…
Most-cited papers in Sirtuins and Resveratrol in Medicine
- Cancer Chemopreventive Activity of Resveratrol, a Natural Product Derived from Grapes · Science · 1997 · 3,999 citations
- Resveratrol improves health and survival of mice on a high-calorie diet · Nature · 2006 · 3,389 citations
- Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase · Nature · 2000 · 2,976 citations
- AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity · Nature · 2009 · 2,957 citations
- Bioavailability of resveratrol · Annals of the New York Academy of Sciences · 2011 · 942 citations
- Anti-Inflammatory Action and Mechanisms of Resveratrol · Molecules · 2021 · 673 citations
- Regulation of SIRT1 and Its Roles in Inflammation · Frontiers in Immunology · 2022 · 525 citations
- Resveratrol (RV): A pharmacological review and call for further research · Biomedicine & Pharmacotherapy · 2021 · 514 citations
- Resveratrol for cancer therapy: Challenges and future perspectives · Cancer Letters · 2021 · 495 citations
- Mitochondrial Sirtuin 3: New emerging biological function and therapeutic target · Theranostics · 2020 · 493 citations
Most recent work
- Oxidative Stress and SIRT1-Nrf2 Anti-Ferroptotic Pathways in Granulosa Cells: A Molecular Key to Follicular Atresia and Ovarian Aging · International Journal of Molecular Sciences · 2026
- Neuropharmacology of synaptic plasticity: pathways to cognitive resilience in healthy aging · 3 Biotech · 2026
- The Multidirectional Biological Activity of Resveratrol: Molecular Mechanisms, Systemic Effects and Therapeutic Potential—A Review · Nutrients · 2026
- The differential impact of three different NAD+ boosters on circulatory NAD and microbial metabolism in humans · Nature Metabolism · 2026
- Targeting the sirtuin 6–NF-κB p65 axis by 6-hydroxyhyoscyamine hydrobromide: a deacetylation-driven new therapy for diabetic wounds · Cellular & Molecular Biology Letters · 2026
- SIRT1: The first key to unlocking the mystery of cardiovascular diseases · Frontiers in Pharmacology · 2026
- Resveratrol for Cancer Treatment: Effects on Metabolism and Immune Cells · Biomolecules · 2026
- Delactylase effects of SIRT3 on a positive feedback loop involving the RUNX1-glycolysis-histone lactylation in diabetic kidney disease · International Journal of Biological Sciences · 2026
- NAD+ hydrolysis catalyzed by SelO is required for mitochondrial homeostasis · Cell · 2026
- Human whole-blood NAD+ levels do not vary with age or lifestyle interventions · Nature Metabolism · 2026
Find a gap in your own Sirtuins and Resveratrol in Medicine sub-topic
This page shows what the Sirtuins and Resveratrol in Medicine literature already flags as unresolved. To narrow it to your specific question, search the Research Gap Finder: the search is free with a free account and lists the papers closest to your topic first. Unlocking that topic (50 credits, charged once) fills the comparison table from our 7.9M-paper local library and writes the gaps from its rows.
Open the Research Gap Finder →